Background Febuxostat,a novel nonpurine selective inhibitor of xanthine oxidase(XO),may be used in the prevention and management of atrial fibrillation(AF).The
0ctogenarians represent the fastest growing group of patients undergoing percutaneous coronary intervention(PCI),now constituting more than one in five patients
Introduction Clopidogrel is a thienopyridine derivative platelet aggregation inhibitor that irreversibly and selectively binding to adenylate cyclase-coupled AD